Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with adverse clinical outcomes, impaired health-related quality of life, and significant economic burden. The growing burden of MASLD and MASH has led to the publication of a large number of MASLD/MASH guidelines by national and international societies. However, important differences among the recommendations have created confusion, contributing to a low implementation rate and suboptimal management of MASLD and MASH. Creating a consensus recommendation has become more important since the approval of a selective agonist of thyroid hormone β receptor (resmetirom) for MASH treatment in…

• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• GS
  Gilead Sciences
• AP
  Alexion Pharmaceuticals
• AP
  Alnylam Pharmaceuticals
• RP
  Regeneron Pharmaceuticals
• IH
  Inova Health System
• IP
  Ionis Pharmaceuticals
• CD
  Centres de Recerca de Catalunya

  Award: 501100011033
• IP
  Inventiva Pharma
• IP
  Intercept Pharmaceuticals
• NB
  NGM Biopharmaceuticals
• M
  Moderna
• MP
  Madrigal Pharmaceuticals
• GD
  Generalitat de Catalunya

  Awards: 10.13039/501100011033, CEX2023-0001290-S, 501100011033, MCIN/AEI/ 10.13039/501100011033
• NN
  Novo Nordisk
• SH
  Siemens Healthineers
• I
  Ipsen
• BH
  Bausch Health
• G
  Genentech
• AE
  Agencia Estatal de Investigación

  Awards: 501100011033, 10.13039/501100011033, AEI/ 10.13039/501100011033, CEX2023-0001290-S, 13039, 10.13039, 13039/501100011033, MCIN/AEI/ 10.13039/501100011033
• UP
  UCB Pharma